Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alovudine in Nucleoside-Experienced HIV-Infected Subjects
NCT02232581Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of alovudine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Mean change in HIV viral load from baseline to Week 4. Started Apr 2004; status: completed.
02
Drugs
alovudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02232581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232581.